HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ABR-238901

S100A9 inhibitor

Networked: 5 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - ABR-238901: 5
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - ABR-238901: 5

Experts

1.	Averitt V, Richard Garland: 1 article (11/2021)
2.	Ding, Zhiyi: 1 article (11/2021)
3.	Du, Feifei: 1 article (11/2021)
4.	Jakobsson, Gabriel: 1 article (11/2021)
5.	Rahman, Milladur: 1 article (11/2021)
6.	Rönnow, Carl-Fredrik: 1 article (11/2021)
7.	Schiopu, Alexandru: 1 article (11/2021)
8.	Thorlacius, Henrik: 1 article (11/2021)
9.	De Beule, Nathan: 1 article (10/2017)
10.	De Bruyne, Elke: 1 article (10/2017)

Related Diseases

1.	Endotoxemia 01/01/2023 - "We used S100A8/A9 blockade with the small-molecule inhibitor ABR-238901 and S100A9-/- mice for therapeutic and mechanistic studies on endotoxemia-induced cardiac dysfunction in mice. "
2.	Sepsis (Septicemia) 01/01/2023 - "Pharmacological blockade of S100A8/A9 with ABR-238901 has potent anti-inflammatory effects, mitigates myocardial dysfunction and might represent a novel therapeutic strategy for patients with severe sepsis."
3.	Left Ventricular Dysfunction 01/01/2023 - "Two ABR-238901 doses (30 mg/kg) administered intraperitoneally with a 6 h interval, starting directly after LPS or at a later time-point when LV dysfunction is fully established, efficiently prevented and reversed the phenotype, respectively. "
4.	Neoplasms (Cancer) 10/01/2017 - "ABR-238901 treatment in vivo reduced angiogenesis but had only minor effects on tumor load as single agent (6% reduction). " 10/01/2017 - "However, ABR-238901 treatment in combination with bortezomib resulted in an increased reduction in tumor load compared with single treatments (50% relative reduction compared with bortezomib alone). "
5.	Cardiomyopathies (Cardiomyopathy) 11/01/2023 - "S100a8/a9 inhibition by ABR-238901 showed a similar heart protective effect against DOX-induced cardiomyopathy to LIPUS treatment. "

Related Drugs and Biologics

1.	Bortezomib (Velcade)